Considering that Runx1 is a downstream target of Sox17, it is tempting to speculate that mutations in the Sox17 enhancer that are associated with increased risk of PAH, may predispose to PH by failing to suppress Runx1 expression. This evidence concerns the gene SOX17 and pulmonary arterial hypertension.